Celiac Disease Genetics — HLA-DQ2, HLA-DQ8 Testing

About this condition

Celiac Disease

Celiac disease is an autoimmune disorder triggered by gluten ingestion in genetically predisposed individuals. Prevalence is approximately 1% worldwide, with higher prevalence in European ancestry populations. Clinical presentation is highly variable: classic presentation includes malabsorption (diarrhea, steatorrhea, weight loss), abdominal pain, and growth failure in children; dermatitis herpetiformis (pruritic skin manifestation) occurs in 15–25% of celiac patients; and non-classical presentations include isolated elevated liver enzymes, anemia, osteoporosis, or neurological symptoms. Diagnosis is made through serological testing (tissue transglutaminase IgA antibody, endomysial antibody) and small bowel biopsy showing villous atrophy. Remarkably, approximately 98.4% of celiac disease patients carry either HLA-DQ2 or HLA-DQ8, making HLA genotyping a powerful diagnostic tool.

HLA-DQ2 and HLA-DQ8 are MHC class II molecules, heterodimers of α and β chains encoded by closely linked genes in the HLA region. HLA-DQ2 is composed of HLA-DQA1*05 and HLA-DQB1*02 chains; HLA-DQ8 comprises HLA-DQA1*03 and HLA-DQB1*03:02. These molecules have peptide-binding pockets with specific anchor residue requirements that complement gluten peptide sequences. The pathogenic mechanism is T cell-mediated: gluten peptides are deamidated by tissue transglutaminase, creating strong MHC ligands for HLA-DQ2 or HLA-DQ8 molecules. Autoreactive T cells recognize these gluten-derived epitopes presented by DQ2/DQ8, triggering Th1 and Th17 responses that drive intestinal inflammation and villous atrophy. Approximately 30–40% of the general population carries DQ2 or DQ8, but only 3–5% develop celiac disease, indicating that additional genetic and environmental factors are required.

HLA-DQ2/DQ8 testing is particularly useful as a rule-out: absence of DQ2 and DQ8 essentially excludes celiac disease with very high negative predictive value (~100%). A negative result in a patient with serological evidence suggesting celiac disease should prompt reconsideration of diagnosis. Positive results confirm HLA risk is present but do not diagnose celiac disease; additional testing (serological and endoscopic) is required. HLA testing is particularly valuable in patients already on a gluten-free diet (serology may be falsely negative), children under 2 years (serology less reliable), and first-degree relatives of celiac patients (10–15% population risk). In asymptomatic at-risk family members, absence of DQ2/DQ8 can reliably remove the need for endoscopic screening.

Gene locus: HLA-DQ2 (6p21.32), HLA-DQ8 (6p21.32)

HLA-DQ2/DQ8 typing is useful for diagnosis support and rule-out in at-risk populations. Standard panels may have limited HLA typing capability.

HLA testing is a powerful rule-out for celiac disease

Absence of HLA-DQ2 and HLA-DQ8 essentially excludes celiac disease with very high negative predictive value (~100%). Standard genetic testing may not include comprehensive HLA-DQA1 and HLA-DQB1 typing. However, HLA testing has limitations: positive results only confirm genetic predisposition, not disease presence, since 30–40% of the general population carries DQ2/DQ8 but only 3–5% develop celiac disease. Whole genome sequencing captures HLA variant data, enabling definitive HLA-DQ2/DQ8 risk assessment for diagnosis support, family screening, and exclusion of celiac disease in diagnostic dilemmas.

HLA genotype determines celiac risk and guides family screening

Patients carrying HLA-DQ2 or HLA-DQ8 are at genetic risk for celiac disease; those who are DQ2/DQ8 negative can be reassured that celiac disease is extremely unlikely. In families with a known celiac patient, HLA-DQ2/DQ8 testing of first-degree relatives identifies who carries genetic risk (and should be serologically screened) and who does not (and can avoid unnecessary monitoring). For patients already on a gluten-free diet, HLA testing helps confirm suspected celiac disease when serology is negative due to dietary gluten avoidance. Documented in the medical record, HLA genotype type prevents unnecessary dietary restriction in non-carriers and focuses surveillance on carriers at true genetic risk.

You've been told it might be IBS, stress, or diet. But the real question is whether your immune system was genetically primed to react to gluten from the start.

Celiac Disease

HLA-DQ2/DQ8 typing is useful for diagnosis support and rule-out in at-risk populations. Standard panels may have limited HLA typing capability.

HLA testing is a powerful rule-out for celiac disease

HLA genotype determines celiac risk and guides family screening

One test. A lifetime of answers.

You've been told it might be IBS, stress, or diet. But the real question is whether your immune system was genetically primed to react to gluten from the start.

Celiac Disease

HLA-DQ2/DQ8 typing is useful for diagnosis support and rule-out in at-risk populations. Standard panels may have limited HLA typing capability.

HLA testing is a powerful rule-out for celiac disease

HLA genotype determines celiac risk and guides family screening

Others in Autoimmune & Inflammatory

One test. A lifetime of answers.